News

uniQure hopeful in gene therapy trial
Enlarge image

Gene TherapyNetherlands

uniQure hopeful in gene therapy trial

08.01.2016 - A new hope for gene therapy: Dutch biotech uniQure has presented promising results from its haemophilia B gene therapy clinical trial. A jump in the company’s shares followed the announcement.

In a low-dose cohort of an ongoing Phase I/II clinical trial being conducted in adult hemophilia B patients, uniQures AAV5/FIX gene therapy, AMT-060, has resulted in encouraging data. Topline results showed that four out of the five patients were able to discontinue prophylactic recombinant factor IX. Two patients’ factor IX rose to 5.5% and 4.5% of the normal level, from below 2% before the treatment.

Haemophilia B patients themselves cannot produce enough factor IX, a protein responsible for blood clotting, leading to excessive bleeding. Patients are currently treated by repeated infusion of recombinant factor IX. uniQure’s gene therapy AMT-060 consists of a codon-optimised wild type FIX gene and the LP1 liver promoter together with the AAV5 viral vector, manufactured using uniQure’s insect cell based manufacturing technology. AMT-060 is administered, without immunosuppressant therapy, through the peripheral vein in a one treatment session for approximately 30 minutes.

“These early data from the low-dose cohort suggest that AMT-060 is generally well-tolerated and capable of successfully transducing the liver resulting in clinically meaningful FIX expression levels,” uniQure said in a statement. Frank W.G. Leebeek an investigator in the study at the Erasmus Medical Center in Rotterdam, added: “Thus far, the overall tolerability and FIX expression profile in the low-dose cohort is encouraging for patients with hemophilia B and support  the continuation of the study.”

Shareholders shared the company’s optimism. uniQure’s shares rose from below US$15 on 6th January, to more than US$17 on the 8th.

“Today, we are the only AAV gene therapy company in the world with both proprietary, commercial-scale manufacturing capabilities and encouraging clinical data across multiple diseases,” commented uniQure CEO Dan Soland.

© european-biotechnology-news.com/um

http://www.european-biotechnology-news.com/news/news/2016-01/uniqure-hopeful-in-gene-therapy-trial.html

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Open InnovationFrance

03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.

FinancingSwitzerlandEU

29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.

Industry reportGermany

27.04.2016 More revenue, more jobs, more financing, more R&D expenditure – all signs point towards sustainable growth in the German biotech sector. These are the results of the most recent company survey 2016, published by biotechnologie.de. The report was once again conducted alongside the biotech standards defined by the organisation for economic cooperation and development (OECD).

Clinical ResearchFrancePortugal

21.04.2016 An expert panel’s final report on the fatal drug trial earlier this year in France states that the death of one of the participants was most likely caused by the drug’s toxicity and not by any violation of the rules.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Berlin (GER)

XIV. BIONNALE 2016

Aachen

Biomedica 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • NOVACYT (F)1.63 EUR17.27%
  • PLETHORA (UK)3.38 GBP12.67%

FLOP

  • BAYER (D)84.42 EUR-5.72%
  • ALMIRALL (E)13.37 EUR-5.51%
  • MOLOGEN (D)3.20 EUR-5.04%

TOP

  • GALAPAGOS (B)51.25 EUR28.6%
  • NICOX (F)10.90 EUR26.2%
  • GENMAB (DK)1205.00 DKK24.2%

FLOP

  • BIONOR PHARMA (N)0.68 NOK-26.9%
  • MOBERG PHARMA (S)38.70 SEK-26.3%
  • BIOCARTIS GROUP NV (B)8.00 EUR-24.2%

TOP

  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • KARO BIO (S)28.90 SEK1906.9%
  • NICOX (F)10.90 EUR489.2%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.90 SEK-86.6%
  • BB BIOTECH (D)43.88 EUR-84.9%
  • EVOCUTIS (UK)0.05 GBP-79.2%

No liability assumed, Date: 23.05.2016